Clinical Trials Directory

Trials / Conditions / Recurrent Burkitt Lymphoma

Recurrent Burkitt Lymphoma

13 registered clinical trials studyying Recurrent Burkitt Lymphoma — 2 currently recruiting.

StatusTrialSponsorPhase
WithdrawnVorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed A
NCT04220008
M.D. Anderson Cancer CenterPhase 2
WithdrawnRituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphom
NCT04285268
Rutgers, The State University of New JerseyPhase 2
Active Not RecruitingNivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lympho
NCT03038672
National Cancer Institute (NCI)Phase 2
RecruitingCombination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lympho
NCT03136146
M.D. Anderson Cancer CenterPhase 2
Active Not RecruitingObinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin
NCT02992522
Beth ChristianPhase 1
Active Not RecruitingNivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
NCT03015896
David Bond, MDPhase 1 / Phase 2
CompletedPembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT02950220
Kami MaddocksPhase 1
CompletedLenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
NCT02568553
National Cancer Institute (NCI)Phase 1
Active Not RecruitingGene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Trans
NCT02797470
AIDS Malignancy ConsortiumPhase 1 / Phase 2
CompletedDose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagno
NCT02199184
M.D. Anderson Cancer CenterPhase 2
CompletedAlisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
NCT01897012
National Cancer Institute (NCI)Phase 1
TerminatedHigh-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Rel
NCT01434472
Fred Hutchinson Cancer CenterPhase 2
RecruitingInotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
NCT01371630
M.D. Anderson Cancer CenterPhase 1 / Phase 2